Global Generic Oncology Drugs Market Research Report 2023
Global Generic Oncology Drugs Market Overview:
Global Generic Oncology Drugs Market Report 2022 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2022-2028.This research study of Generic Oncology Drugs involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Generic Oncology Drugs Market
The Generic Oncology Drugs Market Research report incorporate value chain analysis for each of the product type. Value chain analysis offers in depth information about value addition at each stage.The study includes drivers and restraints for Generic Oncology Drugs Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Generic Oncology Drugs Market helps user to make precise decision in order to expand their market presence and increase market share.
Impact of COVID-19 on Generic Oncology Drugs Market
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Generic Oncology Drugs market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Global Generic Oncology Drugs Market Segmentation
Global Generic Oncology Drugs Market Research report comprises of Porter's five forces analysis to do the detail study about its each segmentation like Product segmentation, End user/application segment analysis and Major key players analysis mentioned as below;
By Type, Generic Oncology Drugs market has been segmented into:
Oral
Parenteral
By Application, Generic Oncology Drugs market has been segmented into:
Hospital pharmacy
Retail pharmacy
Online pharmacy
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Generic Oncology Drugs market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Generic Oncology Drugs market.
Top Key Players Covered in Generic Oncology Drugs market are:
Celgene Corporation
NATCO Pharma Limited
Sun Pharmaceutical Industries Ltd.
Merck & Company
Inc
Pfizer Inc.
Aurobindo Pharma.
GlaxoSmithKline plc
Mylan N.V.
F. Hoffmann-La Roche Ltd
Hikma Pharmaceuticals PLC
Lupin Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
Novartis AG
Objective to buy this Report:
1. Generic Oncology Drugs analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Generic Oncology Drugs market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Global Generic Oncology Drugs Market Report 2022 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2022-2028.This research study of Generic Oncology Drugs involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Generic Oncology Drugs Market
The Generic Oncology Drugs Market Research report incorporate value chain analysis for each of the product type. Value chain analysis offers in depth information about value addition at each stage.The study includes drivers and restraints for Generic Oncology Drugs Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Generic Oncology Drugs Market helps user to make precise decision in order to expand their market presence and increase market share.
Impact of COVID-19 on Generic Oncology Drugs Market
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Generic Oncology Drugs market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Global Generic Oncology Drugs Market Segmentation
Global Generic Oncology Drugs Market Research report comprises of Porter's five forces analysis to do the detail study about its each segmentation like Product segmentation, End user/application segment analysis and Major key players analysis mentioned as below;
By Type, Generic Oncology Drugs market has been segmented into:
Oral
Parenteral
By Application, Generic Oncology Drugs market has been segmented into:
Hospital pharmacy
Retail pharmacy
Online pharmacy
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Generic Oncology Drugs market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Generic Oncology Drugs market.
Top Key Players Covered in Generic Oncology Drugs market are:
Celgene Corporation
NATCO Pharma Limited
Sun Pharmaceutical Industries Ltd.
Merck & Company
Inc
Pfizer Inc.
Aurobindo Pharma.
GlaxoSmithKline plc
Mylan N.V.
F. Hoffmann-La Roche Ltd
Hikma Pharmaceuticals PLC
Lupin Pharmaceuticals
Teva Pharmaceutical Industries Ltd.
Novartis AG
Objective to buy this Report:
1. Generic Oncology Drugs analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Generic Oncology Drugs market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
CHAPTER 1: INTRODUCTION
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
CHAPTER 2:EXECUTIVE SUMMARY
CHAPTER 3:GROWTH OPPORTUNITIES BY SEGMENT
3.1 By Type
3.2 By Application
CHAPTER 4: MARKET LANDSCAPE
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
CHAPTER 5: GENERIC ONCOLOGY DRUGS MARKET BY TYPE
5.1 Generic Oncology Drugs Market Overview Snapshot and Growth Engine
5.2 Generic Oncology Drugs Market Overview
5.3 Oral
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2028F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Oral: Geographic Segmentation
5.4 Parenteral
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2028F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Parenteral: Geographic Segmentation
CHAPTER 6: GENERIC ONCOLOGY DRUGS MARKET BY APPLICATION
6.1 Generic Oncology Drugs Market Overview Snapshot and Growth Engine
6.2 Generic Oncology Drugs Market Overview
6.3 Hospital pharmacy
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2016-2028F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospital pharmacy: Geographic Segmentation
6.4 Retail pharmacy
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2016-2028F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Retail pharmacy: Geographic Segmentation
6.5 Online pharmacy
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2016-2028F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Online pharmacy: Geographic Segmentation
CHAPTER 7: COMPANY PROFILES AND COMPETITIVE ANALYSIS
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Generic Oncology Drugs Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Generic Oncology Drugs Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Generic Oncology Drugs Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 CELGENE CORPORATION
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 NATCO PHARMA LIMITED
7.4 SUN PHARMACEUTICAL INDUSTRIES LTD.
7.5 MERCK & COMPANY
7.6 INC
7.7 PFIZER INC.
7.8 AUROBINDO PHARMA.
7.9 GLAXOSMITHKLINE PLC
7.10 MYLAN N.V.
7.11 F. HOFFMANN-LA ROCHE LTD
7.12 HIKMA PHARMACEUTICALS PLC
7.13 LUPIN PHARMACEUTICALS
7.14 TEVA PHARMACEUTICAL INDUSTRIES LTD.
7.15 NOVARTIS AG
CHAPTER 8: GLOBAL GENERIC ONCOLOGY DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Oral
8.2.2 Parenteral
8.3 Historic and Forecasted Market Size By Application
8.3.1 Hospital pharmacy
8.3.2 Retail pharmacy
8.3.3 Online pharmacy
CHAPTER 9: NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Oral
9.4.2 Parenteral
9.5 Historic and Forecasted Market Size By Application
9.5.1 Hospital pharmacy
9.5.2 Retail pharmacy
9.5.3 Online pharmacy
9.6 Historic and Forecast Market Size by Country
9.6.1 U.S.
9.6.2 Canada
9.6.3 Mexico
CHAPTER 10: EUROPE GENERIC ONCOLOGY DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Oral
10.4.2 Parenteral
10.5 Historic and Forecasted Market Size By Application
10.5.1 Hospital pharmacy
10.5.2 Retail pharmacy
10.5.3 Online pharmacy
10.6 Historic and Forecast Market Size by Country
10.6.1 Germany
10.6.2 U.K.
10.6.3 France
10.6.4 Italy
10.6.5 Russia
10.6.6 Spain
10.6.7 Rest of Europe
CHAPTER 11: ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Oral
11.4.2 Parenteral
11.5 Historic and Forecasted Market Size By Application
11.5.1 Hospital pharmacy
11.5.2 Retail pharmacy
11.5.3 Online pharmacy
11.6 Historic and Forecast Market Size by Country
11.6.1 China
11.6.2 India
11.6.3 Japan
11.6.4 Singapore
11.6.5 Australia
11.6.6 New Zealand
11.6.7 Rest of APAC
CHAPTER 12: MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Oral
12.4.2 Parenteral
12.5 Historic and Forecasted Market Size By Application
12.5.1 Hospital pharmacy
12.5.2 Retail pharmacy
12.5.3 Online pharmacy
12.6 Historic and Forecast Market Size by Country
12.6.1 Turkey
12.6.2 Saudi Arabia
12.6.3 Iran
12.6.4 UAE
12.6.5 Africa
12.6.6 Rest of MEA
CHAPTER 13: SOUTH AMERICA GENERIC ONCOLOGY DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Oral
13.4.2 Parenteral
13.5 Historic and Forecasted Market Size By Application
13.5.1 Hospital pharmacy
13.5.2 Retail pharmacy
13.5.3 Online pharmacy
13.6 Historic and Forecast Market Size by Country
13.6.1 Brazil
13.6.2 Argentina
13.6.3 Rest of SA
CHAPTER 14 INVESTMENT ANALYSIS
CHAPTER 15 ANALYST VIEWPOINT AND CONCLUSION
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
CHAPTER 2:EXECUTIVE SUMMARY
CHAPTER 3:GROWTH OPPORTUNITIES BY SEGMENT
3.1 By Type
3.2 By Application
CHAPTER 4: MARKET LANDSCAPE
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
CHAPTER 5: GENERIC ONCOLOGY DRUGS MARKET BY TYPE
5.1 Generic Oncology Drugs Market Overview Snapshot and Growth Engine
5.2 Generic Oncology Drugs Market Overview
5.3 Oral
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2028F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Oral: Geographic Segmentation
5.4 Parenteral
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2028F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Parenteral: Geographic Segmentation
CHAPTER 6: GENERIC ONCOLOGY DRUGS MARKET BY APPLICATION
6.1 Generic Oncology Drugs Market Overview Snapshot and Growth Engine
6.2 Generic Oncology Drugs Market Overview
6.3 Hospital pharmacy
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2016-2028F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospital pharmacy: Geographic Segmentation
6.4 Retail pharmacy
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2016-2028F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Retail pharmacy: Geographic Segmentation
6.5 Online pharmacy
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2016-2028F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Online pharmacy: Geographic Segmentation
CHAPTER 7: COMPANY PROFILES AND COMPETITIVE ANALYSIS
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Generic Oncology Drugs Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Generic Oncology Drugs Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Generic Oncology Drugs Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 CELGENE CORPORATION
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 NATCO PHARMA LIMITED
7.4 SUN PHARMACEUTICAL INDUSTRIES LTD.
7.5 MERCK & COMPANY
7.6 INC
7.7 PFIZER INC.
7.8 AUROBINDO PHARMA.
7.9 GLAXOSMITHKLINE PLC
7.10 MYLAN N.V.
7.11 F. HOFFMANN-LA ROCHE LTD
7.12 HIKMA PHARMACEUTICALS PLC
7.13 LUPIN PHARMACEUTICALS
7.14 TEVA PHARMACEUTICAL INDUSTRIES LTD.
7.15 NOVARTIS AG
CHAPTER 8: GLOBAL GENERIC ONCOLOGY DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Oral
8.2.2 Parenteral
8.3 Historic and Forecasted Market Size By Application
8.3.1 Hospital pharmacy
8.3.2 Retail pharmacy
8.3.3 Online pharmacy
CHAPTER 9: NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Oral
9.4.2 Parenteral
9.5 Historic and Forecasted Market Size By Application
9.5.1 Hospital pharmacy
9.5.2 Retail pharmacy
9.5.3 Online pharmacy
9.6 Historic and Forecast Market Size by Country
9.6.1 U.S.
9.6.2 Canada
9.6.3 Mexico
CHAPTER 10: EUROPE GENERIC ONCOLOGY DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Oral
10.4.2 Parenteral
10.5 Historic and Forecasted Market Size By Application
10.5.1 Hospital pharmacy
10.5.2 Retail pharmacy
10.5.3 Online pharmacy
10.6 Historic and Forecast Market Size by Country
10.6.1 Germany
10.6.2 U.K.
10.6.3 France
10.6.4 Italy
10.6.5 Russia
10.6.6 Spain
10.6.7 Rest of Europe
CHAPTER 11: ASIA-PACIFIC GENERIC ONCOLOGY DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Oral
11.4.2 Parenteral
11.5 Historic and Forecasted Market Size By Application
11.5.1 Hospital pharmacy
11.5.2 Retail pharmacy
11.5.3 Online pharmacy
11.6 Historic and Forecast Market Size by Country
11.6.1 China
11.6.2 India
11.6.3 Japan
11.6.4 Singapore
11.6.5 Australia
11.6.6 New Zealand
11.6.7 Rest of APAC
CHAPTER 12: MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Oral
12.4.2 Parenteral
12.5 Historic and Forecasted Market Size By Application
12.5.1 Hospital pharmacy
12.5.2 Retail pharmacy
12.5.3 Online pharmacy
12.6 Historic and Forecast Market Size by Country
12.6.1 Turkey
12.6.2 Saudi Arabia
12.6.3 Iran
12.6.4 UAE
12.6.5 Africa
12.6.6 Rest of MEA
CHAPTER 13: SOUTH AMERICA GENERIC ONCOLOGY DRUGS MARKET ANALYSIS, INSIGHTS AND FORECAST, 2016-2028
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Oral
13.4.2 Parenteral
13.5 Historic and Forecasted Market Size By Application
13.5.1 Hospital pharmacy
13.5.2 Retail pharmacy
13.5.3 Online pharmacy
13.6 Historic and Forecast Market Size by Country
13.6.1 Brazil
13.6.2 Argentina
13.6.3 Rest of SA
CHAPTER 14 INVESTMENT ANALYSIS
CHAPTER 15 ANALYST VIEWPOINT AND CONCLUSION
LIST OF TABLES
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. GENERIC ONCOLOGY DRUGS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. GENERIC ONCOLOGY DRUGS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. GENERIC ONCOLOGY DRUGS MARKET COMPETITIVE RIVALRY
TABLE 005. GENERIC ONCOLOGY DRUGS MARKET THREAT OF NEW ENTRANTS
TABLE 006. GENERIC ONCOLOGY DRUGS MARKET THREAT OF SUBSTITUTES
TABLE 007. GENERIC ONCOLOGY DRUGS MARKET BY TYPE
TABLE 008. ORAL MARKET OVERVIEW (2016-2028)
TABLE 009. PARENTERAL MARKET OVERVIEW (2016-2028)
TABLE 010. GENERIC ONCOLOGY DRUGS MARKET BY APPLICATION
TABLE 011. HOSPITAL PHARMACY MARKET OVERVIEW (2016-2028)
TABLE 012. RETAIL PHARMACY MARKET OVERVIEW (2016-2028)
TABLE 013. ONLINE PHARMACY MARKET OVERVIEW (2016-2028)
TABLE 014. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET, BY TYPE (2016-2028)
TABLE 015. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 016. N GENERIC ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 017. EUROPE GENERIC ONCOLOGY DRUGS MARKET, BY TYPE (2016-2028)
TABLE 018. EUROPE GENERIC ONCOLOGY DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 019. GENERIC ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 020. ASIA PACIFIC GENERIC ONCOLOGY DRUGS MARKET, BY TYPE (2016-2028)
TABLE 021. ASIA PACIFIC GENERIC ONCOLOGY DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 022. GENERIC ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 023. MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET, BY TYPE (2016-2028)
TABLE 024. MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 025. GENERIC ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 026. SOUTH AMERICA GENERIC ONCOLOGY DRUGS MARKET, BY TYPE (2016-2028)
TABLE 027. SOUTH AMERICA GENERIC ONCOLOGY DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 028. GENERIC ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 029. CELGENE CORPORATION: SNAPSHOT
TABLE 030. CELGENE CORPORATION: BUSINESS PERFORMANCE
TABLE 031. CELGENE CORPORATION: PRODUCT PORTFOLIO
TABLE 032. CELGENE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 032. NATCO PHARMA LIMITED: SNAPSHOT
TABLE 033. NATCO PHARMA LIMITED: BUSINESS PERFORMANCE
TABLE 034. NATCO PHARMA LIMITED: PRODUCT PORTFOLIO
TABLE 035. NATCO PHARMA LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 035. SUN PHARMACEUTICAL INDUSTRIES LTD.: SNAPSHOT
TABLE 036. SUN PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS PERFORMANCE
TABLE 037. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 038. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 038. MERCK & COMPANY: SNAPSHOT
TABLE 039. MERCK & COMPANY: BUSINESS PERFORMANCE
TABLE 040. MERCK & COMPANY: PRODUCT PORTFOLIO
TABLE 041. MERCK & COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 041. INC: SNAPSHOT
TABLE 042. INC: BUSINESS PERFORMANCE
TABLE 043. INC: PRODUCT PORTFOLIO
TABLE 044. INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 044. PFIZER INC.: SNAPSHOT
TABLE 045. PFIZER INC.: BUSINESS PERFORMANCE
TABLE 046. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 047. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 047. AUROBINDO PHARMA.: SNAPSHOT
TABLE 048. AUROBINDO PHARMA.: BUSINESS PERFORMANCE
TABLE 049. AUROBINDO PHARMA.: PRODUCT PORTFOLIO
TABLE 050. AUROBINDO PHARMA.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 050. GLAXOSMITHKLINE PLC: SNAPSHOT
TABLE 051. GLAXOSMITHKLINE PLC: BUSINESS PERFORMANCE
TABLE 052. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 053. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. MYLAN N.V.: SNAPSHOT
TABLE 054. MYLAN N.V.: BUSINESS PERFORMANCE
TABLE 055. MYLAN N.V.: PRODUCT PORTFOLIO
TABLE 056. MYLAN N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. F. HOFFMANN-LA ROCHE LTD: SNAPSHOT
TABLE 057. F. HOFFMANN-LA ROCHE LTD: BUSINESS PERFORMANCE
TABLE 058. F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 059. F. HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. HIKMA PHARMACEUTICALS PLC: SNAPSHOT
TABLE 060. HIKMA PHARMACEUTICALS PLC: BUSINESS PERFORMANCE
TABLE 061. HIKMA PHARMACEUTICALS PLC: PRODUCT PORTFOLIO
TABLE 062. HIKMA PHARMACEUTICALS PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. LUPIN PHARMACEUTICALS: SNAPSHOT
TABLE 063. LUPIN PHARMACEUTICALS: BUSINESS PERFORMANCE
TABLE 064. LUPIN PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 065. LUPIN PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 065. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SNAPSHOT
TABLE 066. TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS PERFORMANCE
TABLE 067. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 068. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 068. NOVARTIS AG: SNAPSHOT
TABLE 069. NOVARTIS AG: BUSINESS PERFORMANCE
TABLE 070. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 071. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 001. EXECUTIVE SUMMARY
TABLE 002. GENERIC ONCOLOGY DRUGS MARKET BARGAINING POWER OF SUPPLIERS
TABLE 003. GENERIC ONCOLOGY DRUGS MARKET BARGAINING POWER OF CUSTOMERS
TABLE 004. GENERIC ONCOLOGY DRUGS MARKET COMPETITIVE RIVALRY
TABLE 005. GENERIC ONCOLOGY DRUGS MARKET THREAT OF NEW ENTRANTS
TABLE 006. GENERIC ONCOLOGY DRUGS MARKET THREAT OF SUBSTITUTES
TABLE 007. GENERIC ONCOLOGY DRUGS MARKET BY TYPE
TABLE 008. ORAL MARKET OVERVIEW (2016-2028)
TABLE 009. PARENTERAL MARKET OVERVIEW (2016-2028)
TABLE 010. GENERIC ONCOLOGY DRUGS MARKET BY APPLICATION
TABLE 011. HOSPITAL PHARMACY MARKET OVERVIEW (2016-2028)
TABLE 012. RETAIL PHARMACY MARKET OVERVIEW (2016-2028)
TABLE 013. ONLINE PHARMACY MARKET OVERVIEW (2016-2028)
TABLE 014. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET, BY TYPE (2016-2028)
TABLE 015. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 016. N GENERIC ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 017. EUROPE GENERIC ONCOLOGY DRUGS MARKET, BY TYPE (2016-2028)
TABLE 018. EUROPE GENERIC ONCOLOGY DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 019. GENERIC ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 020. ASIA PACIFIC GENERIC ONCOLOGY DRUGS MARKET, BY TYPE (2016-2028)
TABLE 021. ASIA PACIFIC GENERIC ONCOLOGY DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 022. GENERIC ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 023. MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET, BY TYPE (2016-2028)
TABLE 024. MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 025. GENERIC ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 026. SOUTH AMERICA GENERIC ONCOLOGY DRUGS MARKET, BY TYPE (2016-2028)
TABLE 027. SOUTH AMERICA GENERIC ONCOLOGY DRUGS MARKET, BY APPLICATION (2016-2028)
TABLE 028. GENERIC ONCOLOGY DRUGS MARKET, BY COUNTRY (2016-2028)
TABLE 029. CELGENE CORPORATION: SNAPSHOT
TABLE 030. CELGENE CORPORATION: BUSINESS PERFORMANCE
TABLE 031. CELGENE CORPORATION: PRODUCT PORTFOLIO
TABLE 032. CELGENE CORPORATION: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 032. NATCO PHARMA LIMITED: SNAPSHOT
TABLE 033. NATCO PHARMA LIMITED: BUSINESS PERFORMANCE
TABLE 034. NATCO PHARMA LIMITED: PRODUCT PORTFOLIO
TABLE 035. NATCO PHARMA LIMITED: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 035. SUN PHARMACEUTICAL INDUSTRIES LTD.: SNAPSHOT
TABLE 036. SUN PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS PERFORMANCE
TABLE 037. SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 038. SUN PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 038. MERCK & COMPANY: SNAPSHOT
TABLE 039. MERCK & COMPANY: BUSINESS PERFORMANCE
TABLE 040. MERCK & COMPANY: PRODUCT PORTFOLIO
TABLE 041. MERCK & COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 041. INC: SNAPSHOT
TABLE 042. INC: BUSINESS PERFORMANCE
TABLE 043. INC: PRODUCT PORTFOLIO
TABLE 044. INC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 044. PFIZER INC.: SNAPSHOT
TABLE 045. PFIZER INC.: BUSINESS PERFORMANCE
TABLE 046. PFIZER INC.: PRODUCT PORTFOLIO
TABLE 047. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 047. AUROBINDO PHARMA.: SNAPSHOT
TABLE 048. AUROBINDO PHARMA.: BUSINESS PERFORMANCE
TABLE 049. AUROBINDO PHARMA.: PRODUCT PORTFOLIO
TABLE 050. AUROBINDO PHARMA.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 050. GLAXOSMITHKLINE PLC: SNAPSHOT
TABLE 051. GLAXOSMITHKLINE PLC: BUSINESS PERFORMANCE
TABLE 052. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 053. GLAXOSMITHKLINE PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 053. MYLAN N.V.: SNAPSHOT
TABLE 054. MYLAN N.V.: BUSINESS PERFORMANCE
TABLE 055. MYLAN N.V.: PRODUCT PORTFOLIO
TABLE 056. MYLAN N.V.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 056. F. HOFFMANN-LA ROCHE LTD: SNAPSHOT
TABLE 057. F. HOFFMANN-LA ROCHE LTD: BUSINESS PERFORMANCE
TABLE 058. F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 059. F. HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 059. HIKMA PHARMACEUTICALS PLC: SNAPSHOT
TABLE 060. HIKMA PHARMACEUTICALS PLC: BUSINESS PERFORMANCE
TABLE 061. HIKMA PHARMACEUTICALS PLC: PRODUCT PORTFOLIO
TABLE 062. HIKMA PHARMACEUTICALS PLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 062. LUPIN PHARMACEUTICALS: SNAPSHOT
TABLE 063. LUPIN PHARMACEUTICALS: BUSINESS PERFORMANCE
TABLE 064. LUPIN PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 065. LUPIN PHARMACEUTICALS: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 065. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SNAPSHOT
TABLE 066. TEVA PHARMACEUTICAL INDUSTRIES LTD.: BUSINESS PERFORMANCE
TABLE 067. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
TABLE 068. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 068. NOVARTIS AG: SNAPSHOT
TABLE 069. NOVARTIS AG: BUSINESS PERFORMANCE
TABLE 070. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 071. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
LIST OF FIGURES
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. GENERIC ONCOLOGY DRUGS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. GENERIC ONCOLOGY DRUGS MARKET OVERVIEW BY TYPE
FIGURE 012. ORAL MARKET OVERVIEW (2016-2028)
FIGURE 013. PARENTERAL MARKET OVERVIEW (2016-2028)
FIGURE 014. GENERIC ONCOLOGY DRUGS MARKET OVERVIEW BY APPLICATION
FIGURE 015. HOSPITAL PHARMACY MARKET OVERVIEW (2016-2028)
FIGURE 016. RETAIL PHARMACY MARKET OVERVIEW (2016-2028)
FIGURE 017. ONLINE PHARMACY MARKET OVERVIEW (2016-2028)
FIGURE 018. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 019. EUROPE GENERIC ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 020. ASIA PACIFIC GENERIC ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 021. MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 022. SOUTH AMERICA GENERIC ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 001. YEARS CONSIDERED FOR ANALYSIS
FIGURE 002. SCOPE OF THE STUDY
FIGURE 003. GENERIC ONCOLOGY DRUGS MARKET OVERVIEW BY REGIONS
FIGURE 004. PORTER'S FIVE FORCES ANALYSIS
FIGURE 005. BARGAINING POWER OF SUPPLIERS
FIGURE 006. COMPETITIVE RIVALRYFIGURE 007. THREAT OF NEW ENTRANTS
FIGURE 008. THREAT OF SUBSTITUTES
FIGURE 009. VALUE CHAIN ANALYSIS
FIGURE 010. PESTLE ANALYSIS
FIGURE 011. GENERIC ONCOLOGY DRUGS MARKET OVERVIEW BY TYPE
FIGURE 012. ORAL MARKET OVERVIEW (2016-2028)
FIGURE 013. PARENTERAL MARKET OVERVIEW (2016-2028)
FIGURE 014. GENERIC ONCOLOGY DRUGS MARKET OVERVIEW BY APPLICATION
FIGURE 015. HOSPITAL PHARMACY MARKET OVERVIEW (2016-2028)
FIGURE 016. RETAIL PHARMACY MARKET OVERVIEW (2016-2028)
FIGURE 017. ONLINE PHARMACY MARKET OVERVIEW (2016-2028)
FIGURE 018. NORTH AMERICA GENERIC ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 019. EUROPE GENERIC ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 020. ASIA PACIFIC GENERIC ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 021. MIDDLE EAST & AFRICA GENERIC ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
FIGURE 022. SOUTH AMERICA GENERIC ONCOLOGY DRUGS MARKET OVERVIEW BY COUNTRY (2016-2028)
